Genmab Announces U.S. FDA Approval of Arzerra® (ofatumumab) as Extended Treatment for Recurrent or Progressive CLL

Copenhagen, Denmark; January 19, 2016 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for the use of Arzerra® (ofatumumab) for extended treatment of patients who are in complete or partial response after at least two lines of therapy for […]

Read More

After Cancer Treatment

by Amy Johnson, Ph.D. After Treatment Many people with cancer, as well as their friends and family members, eagerly anticipate the day of their last treatment, celebrating with a party or a dinner on that last day. The celebration is often short lived, because, for the patient, the joy they expect is not there, and […]

Read More

Cervical Cancer Awareness

by Sherry Mistro-Henn Medically Reviewed by B. Stephens Dudley, M.D. This year, almost 13,000 women in the US will be diagnosed with cervical cancer. Cervical cancer is defined as cancer found at the lower end of the uterus, between the uterus and vagina. It is the only gynecological cancer that can be diagnosed by a […]

Read More